- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07330245
Erreichen von LLDAS5 bei Patienten mit systemischem Lupus erythematodes, die mit Anifrolumab behandelt werden. (DAHLIA)
DAHLIA: Erreichen eines niedrigen Krankheitsaktivitätsniveaus mit einer Kortikosteroiddosis von weniger als oder gleich 5 mg (LLDAS5): eine Real-Life-Studie mit Anifrolumab bei Patienten mit systemischem Lupus erythematodes in Italien
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
DAHLIA study aims to expand real-world evidence on anifrolumab role in clinical practice, specifically evaluating its effectiveness in achieving and maintenance of LLDAS with a dose of corticosteroids less than or equal to 5 mg/day (LLDAS5). Moreover it will provide data on corticosteroid tapering strategies. Additionally, will be also evaluated the Definitions Of Remission In SLE (DORIS) remission during the study period, as well as the depressive symptoms of these patients.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-Mail: information.center@astrazeneca.com
Studienorte
-
-
-
Ancona, Italien, 60126
- Rekrutierung
- AOU Ospedali Riuniti di Ancona - Presidio Torrette
-
Bari, Italien, 70124
- Zurückgezogen
- Azienda Ospedaliero-Universitaria Policlinico di Bari
-
Brescia, Italien, 25123
- Rekrutierung
- ASST Spedali Civili di Brescia
-
Florence, Italien, 50134
- Rekrutierung
- Azienda Ospedaliero-Universitaria Careggi
-
Milan, Italien
- Noch keine Rekrutierung
- IRCCS Ospedale San Raffaele
-
Milan, Italien, 20122
- Rekrutierung
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, Italien, 41124
- Noch keine Rekrutierung
- Policlinico di Modena - AOU di Modena
-
Naples, Italien
- Noch keine Rekrutierung
- Azienda Ospedaliera Universitaria "Luigi Vanvitelli"
-
Padova, Italien, 35128
- Noch keine Rekrutierung
- Azienda Ospedaliera di Padova
-
Palermo, Italien, 90127
- Rekrutierung
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
-
Pavia, Italien, 27100
- Rekrutierung
- Fondazione IRCCS Policlinico San Matteo
-
Pisa, Italien, 56126
- Noch keine Rekrutierung
- Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara
-
Roma, Italien, 00133
- Noch keine Rekrutierung
- Policlinico Tor Vergata
-
Roma, Italien, 00161
- Rekrutierung
- Policlinico Umberto I - Sapienza Università di Roma
-
Torino, Italien, 10128
- Noch keine Rekrutierung
- Azienda Ospedaliera Ordine Mauriziano Umberto I
-
Trieste, Italien, 34128
- Rekrutierung
- Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI) - Ospedale di Cattinara
-
Udine, Italien, 33100
- Rekrutierung
- ASU Friuli Centrale - Ospedale Santa Maria della Misericordia di Udine
-
Verona, Italien, 37134
- Rekrutierung
- AOUI Verona - Ospedale Borgo Roma
-
-
CA
-
Monserrato, CA, Italien, 09032
- Rekrutierung
- Azienda Ospedaliero-Universitaria di Cagliari Presidio di Monserrato
-
-
Ferrara
-
Cona, Ferrara, Italien, 44124
- Rekrutierung
- Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna
-
-
Foggia
-
San Giovanni Rotondo, Foggia, Italien
- Rekrutierung
- IRCCS Casa Sollievo della Sofferenza
-
-
Milano
-
Rozzano, Milano, Italien, 20089
- Rekrutierung
- IRCCS Humanitas Research Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adult patients with Systemic Lupus Erythematous (SLE) according to 2019 EULAR/ACR classification criteria, treated with anifrolumab as per clinical practices.
Beschreibung
Inclusion Criteria:
- Provided informed consent to participate in the study;
- Aged 18 years or older;
- Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
- Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;
Exclusion Criteria:
- Patients who are at LLDAS5 at the time of study entry;
- Previous exposure to anifrolumab;
- Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy [mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
- Currently participating in any interventional clinical trial with an investigational product;
- Inability to understand and sign the informed consent and to fill in patient questionnaires
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number and percentage of patients achieving LLDAS5
Zeitfenster: 52 weeks
|
proportion of patients with LLDAS5 at 52 weeks, defined as: LLDAS5 is defined as follows:
|
52 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number and percentage of patients reaching LLDAS5 at each time point
Zeitfenster: week 24, 76 and 104
|
Proportion of patients with LLDAS5, according the following definition: LLDAS5 is defined as follows:
|
week 24, 76 and 104
|
|
Number and percentage of patients achieving a GCS (Glucocorticosterioids) dose reduction
Zeitfenster: week 4, 12, 24, 52, 76, 104 vs baseline
|
Number and percentage of patients achieving a GCS dose reduction (to ≤ 5 mg/day; to 0 mg/day) at different timepoints (T1, T2, T3, T4, T5, T6) compared to T0 |
week 4, 12, 24, 52, 76, 104 vs baseline
|
|
Median (range) cumulative dose of GCS
Zeitfenster: from week 0 to week 24; from week 24 to week 52; from week 52 to week 76; from week 76 to week 104
|
Median cumulative dose of GCS calculated at each 6 month period following T0 |
from week 0 to week 24; from week 24 to week 52; from week 52 to week 76; from week 76 to week 104
|
|
Mean(SD) change in tender and swollen joint count
Zeitfenster: week 4, 12, 24, 52, 76 and 104 vs week 0
|
Mean change in tender and swollen joint count using Disease Activity Score 28 (DAS28) map at different timepoints compared to baseline (w0). DAS28 ranges from 0 (no-activity) to 10 (high disease activity) |
week 4, 12, 24, 52, 76 and 104 vs week 0
|
|
mean (SD) change in Power Doppler (PD) Signal Total score
Zeitfenster: week 4, 12, 24, 52, 76 and 104 vs week 0
|
Mean change in Power Doppler (PD) Signal at each time point vs baseline. PD Signal ranges from 0 (low) to 84 (high) |
week 4, 12, 24, 52, 76 and 104 vs week 0
|
|
mean (SD) change in Synovial Hypertrophy (SH) Total score
Zeitfenster: week 4, 12, 24, 52, 76 and 104 vs week 0
|
Mean change in synovial hypertrophy at each time point vs baseline. Synovial hypertrophy ranges from 0 (low) to 84 (high). |
week 4, 12, 24, 52, 76 and 104 vs week 0
|
|
Annualize flaire rate
Zeitfenster: week 52 and week 104
|
Annualized flare rate in the first and second years |
week 52 and week 104
|
|
Number and percentage of patients meeting the DORIS clinical remission
Zeitfenster: week 12, 24, 52, 76 and 104
|
Number and percentage of patients meeting the DORIS clinical remission definition at each timepoints, according to:
|
week 12, 24, 52, 76 and 104
|
|
Number and percentage of patients with sustained DORIS remission
Zeitfenster: week 104
|
Number and percentage of patients with sustained DORIS remission, defined as remaining in remission at or greater than 12 weeks after having met the DORIS definition |
week 104
|
|
Mean (SD) HDRS (Hamilton Depression Rating Scale) total score
Zeitfenster: week 12, 24, 52 and 104 vs week 0
|
Change in HDRS total score at different timepoints compared to T0. HDRS ranges from 0 (no depression) to 54 (severe) |
week 12, 24, 52 and 104 vs week 0
|
|
Mean (SD) PROMIS Depression Short Form 8b (Patient-Reported Outcomes Measurement Information System) total score
Zeitfenster: week 12, 24, 52 and 104 vs week 0
|
Change in PROMIS Depression Short Form 8b total score at different timepoints compared to week 0 (baseline). PROMIS raw scores ranges from 8 (no depression) to 40 (severe) |
week 12, 24, 52 and 104 vs week 0
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- D3461R00093
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .